Table 3

ACF detection by magnification chromoendoscopy

EndpointMCE placebo twice daily (n = 17)MCE celecoxib twice daily (n = 28)Baseline or posttreatment
BaselinePosttreatmentPretreatment-posttreatment differenceBaselinePosttreatmentPretreatment-posttreatment differencePlacebo twice daily (n = 17)Celecoxib twice daily (n = 28)
Total ACF count per group139101−38*233182−51*240415
Average ACF count per patient ± SE8.2 ± 2.45.9 ± 1.72.3 ± 1.78.3 ± 1.76.5 ± 1.51.8 ± 1.114.1 ± 3.814.8 ± 3.1
Total no. patients with ACF detected (%)13 (76.5)12 (70.6)22 (78.6)21 (75.0)14 (82.4)24 (85.7)

Abbreviation: MCE, magnification chromoendoscopy.

  • *For the 35 patients who were not taking cardioprotective aspirin, five ACF per patient were removed at the baseline magnification chromoendoscopy. This could have contributed to the pretreatment-posttreatment difference for both the placebo and celecoxib treatment groups. However, analysis taking this into consideration reveals no significant pretreatment-posttreatment difference for either treatment category. The difference in ACF pretreatment-posttreatment between celecoxib and placebo patients with control for baseline ACF level was 0.5 (95% confidence interval, −2.8-3.7; P = 0.77). When taking into account removal of ACF in non–aspirin-using patients, the difference was −1.0 (95% confidence interval, −2.7-4.6; P = 0.60).

  • One patient with 55 ACF at baseline was an extreme outlier and was assigned the ACF value of the patient with the next to highest value (38) by winsorizing.